MeiraGTx gains; reports over $200 mln in license revenue
13/08/2026 17:03
BUZZ-MeiraGTx gains; reports over $200 mln in license revenue ** Shares of genetic medicine firm MeiraGTx MGTX.O rise 6% to $13.74
** Company reports Q2 revenue of $321.43 million, including $204.6 million in license revenue. There was no license revenue a year earlier
** License revenue relates to MeiraGTx's proprietary gene therapy delivery platform, which enables precise, small-volume brain infusions and has been licensed to Reogen Limited for the development of neurology-focused therapies, including Parkinson's disease
** Including session's move, MGTX shares up 73% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on MeiraGTx Holdings
See all newsU.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
MeiraGTx gains; reports over $200 mln in license revenue
MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
MeiraGTx Q2 revenue jumps on Reogen license revenue
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For Treatment Of Friedreich's Ataxia